Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Remus Pharmaceuticals Ltd

Your Vote -

Buy

66.67%

Hold

0.00%

Sell

33.33%

66.67%

3 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

696.10

200

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

200

Option Chain

Analyzes market sentiment, predicts Remus Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Remus Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    28 May 2026, 3:03PM Remus Pharmaceuticals Limited has informed the Exchange about Transcript
  • Remus Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    21 May 2026, 4:12PM Remus Pharmaceuticals Limited has informed the Exchange regarding audio recordings of Earnings Conference Call for the half year and financial year en
  • Remus Pharma. - Investor Presentation

    21 May 2026, 1:06PM Remus Pharmaceuticals Limited has informed the Exchange about Investor Presentation
  • Remus Pharma. - Appointment

    20 May 2026, 3:36PM Remus Pharmaceuticals Limited has informed the Exchange regarding appointment of M/s Sharp and Tannan Associates as Internal Auditors of the Company
  • Remus Pharma. - Appointment

    20 May 2026, 3:30PM Remus Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr. Tapan Shah as the Secretarial Auditor of the Company for FY 2026-
  • Remus Pharma. - Press Release

    20 May 2026, 3:25PM Remus Pharmaceuticals Limited has informed the Exchange regarding a media release dated May 20, 2026
  • Remus Pharma. - Outcome of Board Meeting

    20 May 2026, 3:19PM Remus Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 20, 2026.
  • Remus Pharma. - Dividend

    20 May 2026, 3:16PM Remus Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 20, 2026, recommended Final Dividend of Rs.
  • Remus Pharma. - Outcome of Board Meeting

    20 May 2026, 3:14PM Remus Pharmaceuticals Limited has submitted to the Exchange the outcome of Board Meeting held on May 20, 2026
  • Remus Pharma. - Price movement

    19 May 2026, 4:48PM Significant movement in price has been observed in Remus Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant
  • Remus Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    16 May 2026, 12:25PM Remus Pharmaceuticals Limited has informed the Exchange regarding Earnings Conference Call for H2-FY26/FY26 scheduled to be held on May 21, 2026
  • Remus Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026

    17 Apr 2026, 8:50PM As of March 2026, 70.95% is owned by Indian Promoters and 29.05% by Public. <p align=justify> Top five Promoters holding highest number of shares of R
  • Remus Pharma. - Structural Digital Database

    17 Apr 2026, 6:19PM Remus Pharmaceuticals Limited has informed the Exchange regarding Compliance Certificate pursuant to the Securities and Exchange Board of India (Prohi
  • Remus Pharma. - Disclosure under SEBI Takeover Regulations

    10 Apr 2026, 3:15PM Remus Pharmaceuticals Limitedÿhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India
  • Remus Pharma. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    7 Apr 2026, 6:18PM Remus Pharmaceuticals Limited has informed the Exchange regarding Disclosure under Regulation 76 of the Securities and Exchange Board of India (Deposi
  • Remus Pharma. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    7 Apr 2026, 6:08PM Remus Pharmaceuticals Limited has informed the Exchange about Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Deposi
  • Remus Pharma. - Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter

    7 Apr 2026, 6:05PM Remus Pharmaceuticals Limited has informed regarding Non-Applicability of the Regulation 27(2) of the Securities and Exchange Board of India (Listing
  • Remus Pharma. - Trading Window

    27 Mar 2026, 12:11PM Remus Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulat
  • Remus Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    17 Mar 2026, 3:43PM Remus Pharmaceuticals Limited has informed the Exchange about Schedule of meet

Key fundamentals

Evaluate the intrinsic value of Remus Pharmaceuticals Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 330.04 244.36 83.5026 27.0783 6.6235
Liabilities 330.04 244.36 83.5026 27.0783 6.6235
Equity 11.78 5.89 1.473 1.085 1
Gross Profit 29.72 25.98 20.0439 10.5464 4.0707
Net Profit 24.71 19.9 16.8197 8.5028 3.3857
Cash From Operating Activities 25.5 15.59 2.4263 5.3129 5.0378
NPM(%) 26.29 25.13 26.48 18.88 13.69
Revenue 93.99 79.16 63.4965 45.0273 24.7171
Expenses 64.27 53.18 43.4526 34.4809 20.6464
ROE(%) 8.04 6.48 5.47 2.76 1.1

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
14 Nov 2025 0.5 5 0 814.8
02 May 2024 4 40 0 6911.75
27 Oct 2023 2 20 0 5537.5

Peers

Other companies within the same industry or sector that are comparable to Remus Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 705.00 -1.55 0.00 0.00 -26.19 0.71
Lotus Eye Hospital and Institute Ltd 108.57 0.25 3619.00 0.00 3.55 0.00
Vaishali Pharma Ltd 7.05 -1.26 0.00 0.00 3.13 0.00
Astec Lifesciences Ltd 770.95 1.27 0.00 0.00 -363.15 0.00

Company Info

The Company was originally incorporated as `Remus Pharmaceuticals Private Limited' as a private limited company, under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat. Later on, pursuant to a special resolution passed by the shareholders in the Extra-Ordinary General Meeting held on January 02, 2023, the Company was converted from a private limited company to public limited company and consequently, the name of the Company was changed to "Remus Pharmaceuticals Limited", and a fresh certificate of incorporation dated January 06, 2023 was issued to the Company by the Registrar of Companies, Ahmedabad. The Corporate Identification Number of the Company is U24232GJ2015PLC084536. MAJOR EVENTS : 2015 - The Company was incorporated as a private limited company under the name "Remus Pharmaceuticals Private Ltd - Conversion of the company from Private Limited to Public Limited Company - Initiation of finished formulation exports and marketing 2019  -Collaboration & partnership with multinational pharmaceuticals 2022  -Initiation of strategic presence in a few key markets 2024-The Company has issued Bonus Shares in the Ratio of 3:1.2025-The Company has issued Bonus Shares in the Ratio of 1:1.

The Company was originally incorporated as `Remus Pharmaceuticals Private Limited' as a private limited company, under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat. Later on, pursuant to a special resolution passed by the shareholders in the Extra-Ordinary General Meeting held on January 02, 2023, the Company was converted from a private limited company to public limited company and consequently, the name of the Company was changed to "Remus Pharmaceuticals Limited", and a fresh certificate of incorporation dated January 06, 2023 was issued to the Company by the Registrar of Companies, Ahmedabad. The Corporate Identification Number of the Company is U24232GJ2015PLC084536. MAJOR EVENTS : 2015 - The Company was incorporated as a private limited company under the name "Remus Pharmaceuticals Private Ltd - Conversion of the company from Private Limited to Public Limited Company - Initiation of finished formulation exports and marketing 2019  -Collaboration & partnership with multinational pharmaceuticals 2022  -Initiation of strategic presence in a few key markets 2024-The Company has issued Bonus Shares in the Ratio of 3:1.2025-The Company has issued Bonus Shares in the Ratio of 1:1.

Read More

Parent Organisation

Remus Pharmaceuticals Ltd.

Founded

21/09/2015

Managing Director

Mr.Arpit Deepakkumar Shah

NSE Symbol

REMUSSM

FAQ

The current price of Remus Pharmaceuticals Ltd is

The 52-week high for Remus Pharmaceuticals Ltd is

The market capitalization of Remus Pharmaceuticals Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Remus Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Remus Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Remus Pharmaceuticals Ltd shares.

The CEO of Remus Pharmaceuticals Ltd is Mr.Arpit Deepakkumar Shah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT